Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug PharmaphorumAfter nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.Rare DiseaseRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaphorum After nearly two years of wrangling, ITF’s Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BMS’ Sotyktu secures EC approval for psoriatic arthritisNext: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher Related Stories Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026 Market Access UK, pharma industry pilot rapid access routes for medicines pharminent July 5, 2026 Market Access Medicare GLP-1 Bridge Launches July 1 With $50 Copays pharminent July 3, 2026
